<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29661905</article-id><article-id pub-id-type="pmc">5902787</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2017817734</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000005323</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1</subject><subject>20</subject><subject>321</subject><subject>176</subject><subject>179</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hewett</surname><given-names>Karen</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Employed by GlaxoSmithKline (study sponsor)as Director, Clinical Development</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Sanders</surname><given-names>Donald B.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>1. Medical Advisory Board, Accordant Health Services 2. DSMB, Alexion Pharmaceuticals Co.</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>TerumoBCT, speaker honorarium</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Royalties for: Single Fiber EMG, Edshagen Publishing House, 2010</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>1. ArGen-X 2. Jacobus Pharmaceutical Co., Inc 3. Modus Outcomes 4. Momenta Pharmaceuticals, Inc. 5. UCB Celltech 6. TerumoBCT 7. GlaxoSmithKline</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Grove</surname><given-names>Richard A.</given-names></name><degrees>MSc</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Use of subcutaneous ofatumumab in multiple sclerosis.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Employed at GlaxoSmithKline since October 1999 as a statistician. Stock/Stock Options, Medical Equipment &#x00026; Materials: I receive GSK shares as part of my contract of employment at GSK where I am a permanent employee since October 1999.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Broderick</surname><given-names>Christine L.</given-names></name><degrees>BS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>GlaxoSmithKline, Operations and Science Lead, 6 years; GlaxoSmithKline, US Monitoring Manager, 6 years; GlaxoSmithKline, Clinical Research Associate, 5 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Rudo</surname><given-names>Todd J.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) GlaxoSmithKline, Medical Director Clinical Safety, 2013-current</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>GlaxoSmithKline employee</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>GlaxoSmithKline 2013-current</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Bassiri</surname><given-names>Ashlyn</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Previous employer: GlaxoSmithKline, Director, 2007-2017 Current employer: Spark Therapeutics, Pharmacovigilance Lead, 2017 to current</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Support for Hamid Bassiri (husband): 1. 2017/07/01-2018/06/30 Children's Hospital of Philadelphia Bassiri, Hamid (PI) Academic Enrichment Fund 2. 2013/07/01-2018/06/30 Children's Hospital of Philadelphia Bassiri, Hamid (PI) Development Fund 3. 2016/05/01-2016/06/20 Protective Immunity and Immunopathology ?Omics? award Bassiri, Hamid (PI) Transcriptional profiling of TH-MYCN neuroblasts</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Support for Hamid Bassiri (husband): 1. 2012/08/06-2016/07/31 National Cancer Institute (NCI) K08 CA166184-01 Bassiri, Hamid (PI) Mechanisms of invariant NKT cell-mediated in vivo anti-tumor responses 2. 2009/07/01-2015/06/30 NIH Loan repayment award - NIAID L40 AI084669 Bassiri, Hamid (PI) (Role: PI) The molecular requirements of NKT cell cytotoxicity</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Support for Hamid Bassiri (husband): 1. 2016/12/01-2018/11/30 Hyundai Hope on wheels Scholar Award Hogarty, Michael (PI); Role: Co-Investigator DFMO combined with GD2-directed immunotherapy to improve neuroblastoma outcomes 2. 2017/1/1-2018/12/31 Alex?s Lemonade Stand Foundation Reach Award Hogarty, Michael (PI); Role: Co-Investigator DFMO synergy with chemo-immunotherapy to eradicate MYC- driven neuroblastoma 3. 2016/12/15-2018/12/14 W. W. Smith Charitable Trust Cancer and AIDS Grant Bassiri, Hamid (PI) Novel iNKT cell-based immunotherapy of high-risk neuroblastoma 4. 2015/07/01-2017/06/30 Canuso Foundation/Center for Childhood Cancer Research Award Bassiri, Hamid (PI) PAD and CAb: A novel combinational immunotherapy for neuroblastoma 5. 2015/01/01-2016/06/30 Wipe Out Kids Cancer Foundation Hogarty, Michael (PI); Role: Co-Investigator Polyamine depletion as a therapeutic strategy for improving neuroblastoma outcome 6. 2015/12/01-2016/06/30 Stand Up to Cancer ? St. Baldrick?s Foundation Pediatric Dream Team subaward Maris, John (PI); Role: Subaward PI Transcriptional and functional profiling of the TH-MYCN tumor immunoenvironment 7. 2015/01/01-2015/12/31 American Cancer Society IRG-78-002-36 Bassiri, Hamid (PI) Augmenting iNKT cell-mediated antitumor immunity</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>Hamid Bassiri (husband): Expert testimony for National Vaccine Injury Compensation Program</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Zvartau-Hind</surname><given-names>Marina</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Employed by GSK - all travel covered by GSK</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Employed by GSK 15 years. Vice-President, Medicines Development Leader. I led the project on behalf of GSK</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Salary from GSK - my employer</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Medical Research Council Board member expense compensation</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>GSK Stock and stock options (employee programs)</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bril</surname><given-names>Vera</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(2) CSL Behring (2) Baxalta (2) Grifols (2) Argenyx (2) Octapharma (2) Alpha Technologies (3) Powell Mansfield Inc</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(2) CSL Behring</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>PLoS One, editorial board member starting 2016</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(2) CSL Behring, Grifols, Bionevia, Octapharma, Powell Mansfield Inc, Argenyx, Alpha Technologies, Baxalta</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(2) CSL Behring, Grifols, Bionevia, Octapharma, Baxalta, ArgenX</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Toronto General/Toronto Western Hospital Foundation GBS/CIDP Foundation International</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><collab>On behalf of the BEL115123 Study Group</collab></contrib><aff>From GSK (K.H.), Stevenage, Herts, UK; Department of Neurology (D.B.S.), Duke University School of Medicine, Durham, NC; GSK (R.A.G.), Uxbridge, Middlesex, UK; GSK (C.L.B., T.J.R., A.B.), Philadelphia, PA; GSK (M.Z.-H.), Brentford, London, UK; and University Health Network (V.B.), University of Toronto, Canada.</aff></contrib-group><contrib-group content-type="collaborators"><contrib contrib-type="collab"><collab>BEL115123 Study Group</collab></contrib><contrib contrib-type="collab"><name><surname>Adams</surname><given-names>Laurence</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bandyopadhyay</surname><given-names>Sankar</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Beydoun</surname><given-names>Said</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bischof</surname><given-names>Felix</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Dimachkie</surname><given-names>Mazen</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Freimer</surname><given-names>Miriam</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Inghilleri</surname><given-names>Maurizio</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Kaminski</surname><given-names>Henry</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mantegazza</surname><given-names>Renato</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Mozaffar</surname><given-names>Tahseen</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Nicolle</surname><given-names>Michael</given-names></name><degrees>MD, FRCPC, DPhil</degrees></contrib><contrib contrib-type="collab"><name><surname>Sharma</surname><given-names>Khema</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Siddiqi</surname><given-names>Zaeemi</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Simpson</surname><given-names>Ericka</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bergh</surname><given-names>Florian Then</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Vu</surname><given-names>Tuan</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Aly</surname><given-names>Radwa</given-names></name><degrees>MSc</degrees></contrib><contrib contrib-type="collab"><name><surname>Antozzi</surname><given-names>Carlo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Barohn</surname><given-names>Richard J.</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Blackmore</surname><given-names>Derrick</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Bonanno</surname><given-names>Silvia</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Campanella</surname><given-names>Angela</given-names></name><degrees>MSc</degrees></contrib><contrib contrib-type="collab"><name><surname>Cash</surname><given-names>Tiyonnoh</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Elsheikh</surname><given-names>Bakri</given-names></name><degrees>MBBS</degrees></contrib><contrib contrib-type="collab"><name><surname>Frasca</surname><given-names>Vittorio</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Goyal</surname><given-names>Namita</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Harvey</surname><given-names>Brittany</given-names></name><degrees>BA</degrees></contrib><contrib contrib-type="collab"><name><surname>Lai</surname><given-names>Eugene</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="collab"><name><surname>Maggi</surname><given-names>Lorenzo</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Minton</surname><given-names>Brian</given-names></name><degrees>BS</degrees></contrib><contrib contrib-type="collab"><name><surname>Martin</surname><given-names>Veronica</given-names></name><degrees>MAE</degrees></contrib><contrib contrib-type="collab"><name><surname>Onesti</surname><given-names>Emanuela</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Pasnoor</surname><given-names>Mamatha</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Roy</surname><given-names>Gulmohor</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Shroff</surname><given-names>Sheetal</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="collab"><name><surname>Thonhoff</surname><given-names>Jason</given-names></name><degrees>MD, PhD</degrees></contrib></contrib-group><author-notes><corresp><bold>Correspondence</bold> Prof. Bril <email>vera.bril@utoronto.ca</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000005323">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p></fn><fn fn-type="other"><p>Coinvestigators are listed at <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A372">links.lww.com/WNL/A372</ext-link>.</p></fn><fn fn-type="other"><p>The Article Processing Charge was funded by GSK.</p></fn></author-notes><pub-date pub-type="ppub"><day>17</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>90</volume><issue>16</issue><fpage>e1425</fpage><lpage>e1434</lpage><history><date date-type="received"><day>26</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2017817734.pdf"/><abstract><sec><title>Objective</title><p>To investigate the efficacy and safety of belimumab, a fully human immunoglobulin G1&#x003bb; monoclonal antibody against B-lymphocyte stimulator, in participants with generalized myasthenia gravis (MG) who remained symptomatic despite standard of care (SoC) therapy.</p></sec><sec><title>Methods</title><p>Eligible participants with MG were randomized 1:1 to receive IV belimumab 10 mg/kg or placebo in this phase II, placebo-controlled, multicenter, double-blind study (NCT01480596; BEL115123). Participants received SoC therapies throughout the 24-week treatment phase and 12-week follow-up period. The primary efficacy endpoint was mean change from baseline in the Quantitative Myasthenia Gravis (QMG) scale at week 24; safety assessments included the frequency and severity of adverse events (AEs) and serious AEs.</p></sec><sec><title>Results</title><p>Forty participants were randomized (placebo n = 22; belimumab n = 18). The mean change in QMG score from baseline at week 24 was not significantly different for belimumab vs placebo (<italic>p</italic> = 0.256). There were no statistically significant differences between treatment groups for secondary endpoints, including the MG Composite and MG&#x02013;Activity of Daily Living scores. Acetylcholine receptor antibody levels decreased over time in both treatment groups. No unexpected AEs were identified and occurrence was similar in the belimumab (78%) and placebo (91%) groups. One participant receiving placebo died (severe sepsis) during the treatment phase.</p></sec><sec><title>Conclusions</title><p>The primary endpoint was not met for belimumab in participants with generalized MG receiving SoC. There was no significant difference in mean change in the QMG score at week 24 for belimumab vs placebo. The safety profile of belimumab was consistent with previous systemic lupus erythematosus studies.</p></sec><sec><title>Classification of evidence</title><p>This study provides Class I evidence that for participants with generalized MG, belimumab did not significantly improve QMG score compared with placebo.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>STATUS</meta-name><meta-value>ONLINE-ONLY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Myasthenia gravis (MG), an acquired autoimmune disorder of neuromuscular transmission, affects over 700,000 people worldwide.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Approximately 85% of generalized MG cases are associated with postsynaptic nicotinic acetylcholine receptor (AChR) antibodies at the motor endplate<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> and reduced functional AChRs.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Approximately 5%&#x02013;8% of patients have muscle-specific tyrosine kinase (MuSK) antibodies.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Lipoprotein receptor&#x02013;related protein 4 antibodies may also be clinically relevant.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup></p><p>Numerous (predominantly off-label) treatments are prescribed for MG, as summarized in a recent international consensus guidance statement for MG treatment by a Task Force of the Myasthenia Gravis Foundation of America.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Many patients do not achieve adequate clinical response, having substantial disability despite treatment.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Developing a therapy suitable for all patients is challenging due to disease heterogeneity.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Acetylcholinesterase inhibitors (e.g., pyridostigmine) are considered first-line treatments for MG; however, patients with anti-MuSK antibodies often respond poorly.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Glucocorticoids or nonsteroidal immunosuppressant therapy are recommended in patients failing to meet treatment goals following an adequate pyridostigmine trial.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><p>Belimumab (Benlysta, Rockville, MD), a human immunoglobulin (Ig) G1&#x003bb; monoclonal antibody against B-lymphocyte stimulator (BLyS), is licensed for adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard SLE therapy.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> Elevated BLyS levels have been identified in patients with MG,<sup><xref rid="R11" ref-type="bibr">11</xref><xref ref-type="bibr" rid="R12">&#x02013;</xref><xref rid="R13" ref-type="bibr">13</xref></sup> highlighting it as a potential treatment target. Other monoclonal antibodies (e.g., rituximab and eculizumab) targeting different immune elements have demonstrated promising results.<sup><xref rid="R14" ref-type="bibr">14</xref><xref ref-type="bibr" rid="R15">&#x02013;</xref><xref rid="R17" ref-type="bibr">17</xref></sup></p><p>This study investigated the efficacy and safety of belimumab in participants with active generalized MG despite receiving standard therapy.</p><sec sec-type="methods" id="s1"><title>Methods</title><sec id="s1-1"><title>Study design</title><p>This phase II, randomized, placebo-controlled, double-blind study (BEL115123) was conducted at 13 centers in Canada, United States, Germany, and Italy between April 2013 and October 2015. Randomization was performed centrally using a computer-generated randomization schedule, created by the study statistician, stratified by antibody status. Randomization numbers were allocated to participants by an interactive voice recognition system. Blinding was maintained throughout the study until the final on-treatment assessment (week 24) for the final participant had been completed, entered into the database, and the initial database lock had been performed for the primary analysis. While the follow-up section of the study was ongoing, the results of the primary analysis were made available only to a limited group of sponsor personnel; neither the study participants nor the study site personnel were aware of results or of the treatment received. All GSK local operating companies, monitors, and investigators remained blinded until completion of the final analysis at the end of the follow-up phase (week 36). Eligible participants were randomized 1:1 to receive either IV belimumab 10 mg/kg or placebo (weeks 0, 2, 4, 8, 12, 16, and 20), and were stratified by antibody screening (AChR/MuSK). Participants were maintained on standard of care (SoC) therapies throughout. The treatment regimen was selected according to the results of 2 pivotal phase III SLE studies (BLISS-52, NCT00424476 and BLISS-76, NCT00410384).<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Belimumab 10 mg/kg, administered IV, resulted in a statistically significant (BLISS-52) and numerically greater (BLISS-76) improvement in the primary efficacy endpoint (SLE Responder Index) compared with placebo by week 24.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Consequently, a 4-week screening period, 24-week treatment period, and 12-week follow-up period (during which no investigational treatment was administered) was employed for this study.</p></sec><sec id="s1-2"><title>Standard protocol approvals, registrations, and participant consents</title><p>This study (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> identifier NCT01480596) was performed in accordance with the International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice guidelines, the ethical procedures outlined in the Declaration of Helsinki,<sup><xref rid="R20" ref-type="bibr">20</xref></sup> and applicable country-specific requirements. Written informed consent was obtained from each participant prior to any study-specific procedures.</p></sec></sec><sec id="s2"><title>Participants</title><sec id="s2-1"><title>Inclusion criteria</title><p>Eligible participants had generalized MG (Myasthenia Gravis Foundation of America [MGFA] Class II&#x02013;IVa inclusive),<sup><xref rid="R21" ref-type="bibr">21</xref></sup> were &#x02265;18 years of age, were positive for AChR/MuSK antibodies, and had a Quantitative MG (QMG) score<sup><xref rid="R22" ref-type="bibr">22</xref></sup> of &#x02265;8, of which &#x02265;4 points were derived from signs other than ocular. At entry to the study, participants must have been receiving a stable dose of one or more of the following MG treatments<sup><xref rid="R1" ref-type="bibr">1</xref></sup>: a cholinesterase inhibitor for a minimum of 2 weeks prior to screening and/or<sup><xref rid="R2" ref-type="bibr">2</xref></sup> prednisone (minimum 1 month) and/or<sup><xref rid="R3" ref-type="bibr">3</xref></sup> one of the following immunosuppressants: cyclosporine (minimum 3 months), methotrexate (minimum 3 months), azathioprine (minimum 6 months), or mycophenolate (minimum 6 months). Female participants were eligible for enrollment provided they were of nonchildbearing potential or of childbearing potential and not pregnant or nursing and agreed to several predefined criteria designed to prevent pregnancy from enrollment to 16 weeks post last dose of study treatment.</p></sec><sec id="s2-2"><title>Exclusion criteria</title><p>Key exclusion criteria included presence or history of thymoma, thymectomy within 12 months, and treatment with IV immunoglobulin (Ig) or plasma exchange (PLEX) within 4 weeks prior to screening or potential requirement for these treatments during the study. Participants were excluded if they had received treatment with rituximab or eculizumab within 12 months of screening, or with any other B cell&#x02013;targeted therapy (including belimumab) at any time; treatment with any immunosuppressive agent other than those permitted within the inclusion criteria within 6 months; or a history of recurrent or chronic infection or currently active systemic infection.</p></sec><sec id="s2-3"><title>Objectives</title><p>The primary objective of this study was to investigate the efficacy of belimumab vs placebo in reducing signs of MG, measured by QMG score, in participants who remained symptomatic (defined by QMG score) on SoC therapy. Secondary objectives included additional efficacy assessments, safety, and tolerability; modulation of AChR/MuSK antibody levels; and pharmacodynamic/biomarker assays. This study aimed to provide Class I evidence for the efficacy and safety of belimumab in participants with MG.</p></sec><sec id="s2-4"><title>Endpoints</title><sec id="s2-4-1"><title>Efficacy endpoints</title><p>The primary endpoint was mean change from baseline in QMG score at week 24 compared with baseline. Secondary efficacy endpoints were mean change from baseline in the MG Composite Score (MGC)<sup><xref rid="R23" ref-type="bibr">23</xref></sup> at week 24 and mean change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale<sup><xref rid="R24" ref-type="bibr">24</xref></sup> at weeks 12 and 24. The proportion of participants with &#x02265;3-point QMG/MGC improvement or worsening from baseline by week 24 and with a sustained improvement of &#x02265;3 points from baseline at week 12 maintained to week 24 were also analyzed. Mean changes from baseline in QMG, MGC, and MG-ADL scores were assessed during the follow-up period at weeks 28, 32, and 36. The MGFA postintervention status,<sup><xref rid="R21" ref-type="bibr">21</xref></sup> despite being a secondary efficacy endpoint, was not analyzed due to inconsistent data collection across sites.</p></sec></sec><sec id="s2-5"><title>Safety endpoints</title><p>Safety endpoints (treatment and follow-up phases) included the frequency and severity of adverse events (AEs), serious AEs (SAEs), the percentage of participants with drug-related AEs, and those withdrawing due to AEs. Predefined AEs of special interest (AESI) included malignancies, hypersensitivity and infusion reactions, opportunistic infections, and suicidality. Changes from baseline, proportion of participants with values of potential clinical concern (vital signs, hematology and clinical chemistry parameters), and incidence of antibelimumab immunogenicity were assessed.</p></sec><sec id="s2-6"><title>Pharmacodynamic/biomarker endpoints</title><p>Change from baseline in AChR/MuSK antibody titers and in B- and T-cell counts were analyzed at weeks 8, 24, 28, and 36.</p></sec><sec id="s2-7"><title>Pharmacokinetic endpoints</title><p>Serum concentrations of belimumab were measured at day 0 and weeks 2, 8, 20, 24, and 28.</p></sec><sec id="s2-8"><title>Statistical analyses</title><p>The estimated sample size was 42 participants to obtain completion of at least one postbaseline efficacy assessment by a minimum of 38 participants, providing at least 80% power to detect a treatment difference of 4.0 for the primary endpoint, assuming a SD of 4.25 utilizing <italic>t</italic> test methodology.</p><p>The safety population comprised all participants who had at least one infusion of the study agent. The intention-to-treat (ITT) population included all participants in the safety population who had any posttreatment efficacy assessment; this was the primary efficacy analysis population. The per protocol (PP) population was a subset of the ITT population who were not major protocol violators. The PP population was used as a sensitivity analysis, including analysis of variance on last observation carried forward (LOCF) values, for the primary endpoint only.</p><p>Change from baseline in QMG score at week 24 was analyzed using a mixed model for repeated measures (MMRM), adjusting for treatment group, visit, baseline QMG score, visit by treatment group interaction, and visit by baseline QMG score interaction. The MMRM models fitted participants as a random effect and used an unstructured covariance matrix.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Given the exploratory nature of the study, Bayesian interpretation for the MMRM analysis of QMG and MGC assuming noninformative priors was also generated, and posterior probabilities that the treatment difference was &#x0003e;0 were derived. A significant <italic>p</italic> value from a frequentist 2-sided test at the 5% level (<italic>p</italic> &#x0003c; 0.05) is equivalent to the posterior probability exceeding 0.975 (i.e., statistical significance occurs at the &#x003b1;% level for a 2-sided test with no multiplicity adjustment when the PP exceeds 1 &#x02212; ([&#x003b1;/100]/2).<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p>Secondary efficacy analyses of continuous data were performed using similar MMRM methods as the primary analysis. Analyses comparing the proportion of participants were planned for Cochran-Mantel-Haenszel &#x003c7;<sup>2</sup> analyses using the observed data, where missing data were assumed to be a negative response. Due to very low response rates, proportions of participants improving or worsening were analyzed using exact methodology with tests stratified by the observed median baseline score (&#x02264; median, &#x0003e; median).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Study population and participant disposition</title><p>Forty participants were randomized (belimumab n = 18; placebo n = 22) (<xref ref-type="fig" rid="F1">figure 1</xref>)<italic>.</italic> Demographic characteristics and baseline medical and MG history were balanced between the treatment groups. Baseline MG severity, measured by QMG, MGC, and MG-ADL, were in the mild to moderate range; median QMG scores (range) were 12.00 (8.0, 19.5) and 12.50 (6.50, 23.0) for belimumab and placebo, respectively (<xref ref-type="table" rid="T1">table 1</xref>). Participants were predominantly female (62%) with a mean (SD) age of 56.1 (15.67) years, and a mean (SD) MG symptom duration of 9.0 (8.13) (placebo) or 8.7 (9.00) (belimumab) years. Most participants had AChR antibodies; 2 participants, both in the placebo group, had MuSK antibodies.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>CONSORT diagram</title></caption><graphic xlink:href="NEUROLOGY2017817734FF1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic baseline characteristics, myasthenia gravis (MG) history, baseline MG disease, and concomitant MG medications taken during the treatment phase (intention-to-treat population)</p></caption><graphic xlink:href="NEUROLOGY2017817734TT1"/></table-wrap></sec><sec id="s3-2"><title>Efficacy</title><p>The primary endpoint, QMG mean change (standard error) from baseline at week 24, was &#x02212;4.21 (1.14) compared with &#x02212;2.37 (1.10) for placebo (<xref ref-type="fig" rid="F2">figure 2A</xref>). However, the treatment difference (1.84 points) was not statistically significant (<italic>p</italic> = 0.256) (<xref ref-type="table" rid="T2">table 2</xref>). Nevertheless, posterior probability analysis did indicate a signal of potential efficacy (posterior probability &#x0003e;0.8). Further comparisons of belimumab vs placebo were made for QMG mean change from baseline at week 24 to assess the sensitivity of the analyses to the effects of protocol violations and missing data. These analyses (PP population and LOCF) also demonstrated no significant difference between belimumab and placebo (<italic>p</italic> = 0.267 and 0.187, respectively) (<xref ref-type="table" rid="T2">table 2</xref>). A change of &#x02265;3 points in QMG score was seen in 61% of belimumab participants vs 29% of placebo participants (<italic>p</italic> = 0.082), while only 44% vs 24%, respectively (<italic>p</italic> = 0.184), demonstrated a sustained change of &#x02265;3 points.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Adjusted mean change from baseline in Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Composite (MGC), and Myasthenia Gravis Activities of Daily Living (MG-ADL) (mixed model for repeated measures [MMRM])</title><p>(A) QMG. (B) MGC. (C) MG-ADL (MMRM). Data represent the intention-to-treat (ITT) population. Negative score is indicative of an improvement. The MMRM analysis method was adjusted for treatment and visit baseline scale score, treatment by visit, and baseline scale score by visit. The QMG score at baseline is the average of the screening and week 0 baseline scores. The MGC and MG-ADL score at baseline was the week 0 baseline score. CI = confidence interval.</p></caption><graphic xlink:href="NEUROLOGY2017817734FF2"/></fig><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Mixed model for repeated measures (MMRM) analysis of change from baseline in Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Composite (MGC), and Myasthenia Gravis Activities of Daily Living (MG-ADL) at weeks 24 and 36, and proportion of participants with improved, worsening, or sustained improvement in QMG/MGC scores at week 24</p></caption><graphic xlink:href="NEUROLOGY2017817734TT2"/><graphic xlink:href="NEUROLOGY2017817734TT2A"/></table-wrap><p>There was no difference between the 2 treatment groups for the mean change from baseline in MGC or MG-ADL score at week 24 or at week 36; the MGC and MG-ADL scores decreased by a similar amount in both groups (<xref ref-type="fig" rid="F2">figure 2, B and C</xref>). The proportion of participants improving by &#x02265;3 points in MGC score was similar in both placebo (48%) and belimumab (50%) groups. A greater proportion of belimumab (39%) than placebo (19%) participants had a sustained improvement; this was not statistically significant (<italic>p</italic> = 0.175). Slightly more participants worsened (&#x02265;3 points) in placebo vs belimumab (24% vs 11%, respectively; <italic>p</italic> = 0.530).</p></sec><sec id="s3-3"><title>Safety</title><p>A similar proportion of participants reported AEs in the belimumab (78%) and placebo (91%) groups during the treatment phase (<xref ref-type="table" rid="T3">table 3</xref>). The most common were influenza and nausea (belimumab group) and diarrhea, back pain, and headache (placebo group). Treatment-related AEs were similar across groups: 32% (placebo) and 28% (belimumab). Five SAEs (nephrolithiasis, sepsis, ruptured aortic dissection, MG exacerbation, and cholelithiasis) were reported in 4 (18%) participants in the placebo group only. The MG exacerbation was treated with PLEX; this participant was withdrawn from the study. Severe AEs occurred in 5 (23%) participants receiving placebo and 1 (6%) participant in the belimumab group. One participant receiving placebo died due to severe sepsis; concomitant medications for this participant included azathioprine. Twelve participants in the placebo (55%) and belimumab (67%) groups experienced AEs during the follow-up phase, with severe AEs reported in 1 (5%) participant receiving placebo and 3 (17%) participants receiving belimumab. Three participants (placebo group) had AEs that led to withdrawal from the study; all were classified as SAEs. No deaths occurred during follow-up.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Participants reporting adverse events (AEs) during the study (safety population)</p></caption><graphic xlink:href="NEUROLOGY2017817734TT3"/></table-wrap><p>AESI were reported in 5 (23%) and 4 (22%) participants (treatment phase) in the placebo and belimumab groups, respectively; the most common events were postinfusion systemic reactions. No malignancies, opportunistic infections, or suicidality events were reported in the study. Clinical chemistry, hematology, liver function, and vital sign measurements revealed no findings of clinical relevance.</p></sec><sec id="s3-4"><title>Pharmacodynamic/biomarker results</title><p>Two participants with MuSK antibodies were identified (placebo group); all other participants had AChR antibodies. A small decrease in AChR antibody titers occurred in both treatment groups during the treatment phase; these returned to baseline levels during follow-up (figure e-1A, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A370">links.lww.com/WNL/A370</ext-link>). No relationship was observed between efficacy and percentage change in antibody levels from baseline to week 24 (overall correlation coefficients: QMG &#x02212;0.025; MGC &#x02212;0.090) (figure e-1, B and C).</p></sec><sec id="s3-5"><title>Pharmacokinetics results</title><p>Pharmacokinetic results are presented in table e-1 (<ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A371">links.lww.com/WNL/A371</ext-link>). Steady-state belimumab concentrations were reached early in the trial and maintained throughout the treatment period.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This phase II study evaluated the efficacy and safety of belimumab in participants with generalized MG who remained symptomatic while on SoC therapy. The primary endpoint (mean change from baseline in the QMG score at week 24) was not met. Although the data showed a small numerical improvement in favor of belimumab, this was not statistically significant and the treatment difference of &#x0223c;2 points was below that considered to be clinically meaningful (3&#x02013;4 points).<sup><xref rid="R27" ref-type="bibr">27</xref></sup> In this study, posterior probability analysis indicated a signal of potential efficacy (posterior probability &#x0003e;0.8). Further analysis of the QMG scale data showed that, while not statistically significant, a higher proportion of participants improved with belimumab treatment compared with placebo at week 24, and demonstrated sustained improvement from weeks 12&#x02013;24. This endpoint has been widely used in nonregulatory MG clinical trials and provides a validated measure of muscle strength.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup></p><p>There was no difference between belimumab and placebo for mean change from baseline for MGC and MG-ADL (week 24 and 36). Mean change from baseline in QMG score, and the proportion of participants improving as measured by QMG, demonstrated a slight numerical improvement over placebo. Overall, the QMG, MGC, and MG-ADL scales all indicated a lack of belimumab effect. The MGC, a validated MG rating scale recommended by the MGFA taskforce,<sup><xref rid="R28" ref-type="bibr">28</xref></sup> differs from the QMG in 2 key aspects: (1) it is a weighted scale where symptoms considered to have a greater effect on the patient are given a higher score; (2) it takes into account the patient's own view of his or her symptoms. The QMG, by contrast, is entirely physician-assessed and scores all symptoms on the same scale<sup><xref rid="R22" ref-type="bibr">22</xref></sup>; such differences may explain the slight improvement observed in the QMG score compared with either MGC or MG-ADL.</p><p>Belimumab serum concentrations were as expected based on prior clinical experience in 2 phase III registration studies in SLE.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Decreased naive B-cell and increased memory B-cell counts were seen following belimumab treatment; given the inhibitory effect of belimumab on B cells, this was not unexpected and has previously been reported in SLE.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> No correlation between efficacy (QMG or MGC) and change in antibody levels was seen. Longer periods of time may be required to observe alterations in antibody level; some autoantibodies require 1&#x02013;2 years of belimumab treatment to be significantly reduced.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> In addition, peripheral antibody titers may not be a valid marker of the neuromuscular junction process. This lack of correlation is consistent with previous observations in MG.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup></p><p>The safety profile for belimumab was consistent with that seen in SLE studies; no new safety signals were identified in this generalized MG population and only one death was reported (placebo group).<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup></p><p>This study has several limitations. Participants recruited were already receiving SoC therapy. The mild level of severity in the population studied here may have contributed to scale insensitivity and floor effects (i.e., the lower limits of the QMG scale were higher than the corresponding disease severity). Participants recruited for the current study may have achieved a symptom plateau, thus reducing the likelihood of further improvement with belimumab. A prior study of patients with more severe MG (QMG baseline score of &#x02265;12) did identify a response to eculizumab treatment.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> The inclusion of participants with more severe MG may have resulted in an improved outcome. Lack of MuSK participants may have contributed to the lack of efficacy. Indeed, case studies with B-cell-targeting rituximab have reported improved and longer-lasting clinical benefit in patients with MuSK MG than those with AChR antibodies.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Finally, this was a small study (n = 40); as such, considerable variability in the dataset may be expected, with small participant numbers driving the observations seen.</p><p>Several emerging therapies for MG have shown promising results. Rituximab, which targets B cells, albeit differently from belimumab, has demonstrated improved clinical outcomes and reduced immunotherapy requirements in a number of retrospective case studies of MG.<sup><xref rid="R14" ref-type="bibr">14</xref><xref ref-type="bibr" rid="R15">&#x02013;</xref><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> No published, adequately powered, randomized, controlled trials of rituximab in MG currently exist. Eculizumab, a humanized monoclonal antibody that blocks complement activation, has shown significant clinical benefit for the improvement of MG compared with placebo in a small (n = 14) randomized phase II study.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> In a larger (n = 125) phase III study of patients with an MG-ADL total score &#x02265;6 who had previously failed treatment, the primary endpoint, change in MG-ADL, did not reach statistical significance. Statistical significance was achieved for several prespecified analyses.<sup><xref rid="R35" ref-type="bibr">35</xref></sup></p><p>This study did not meet its primary endpoint and belimumab demonstrated no significant efficacy compared with placebo in participants with generalized MG who were receiving SoC treatments.</p></sec></body><back><fn-group><fn fn-type="supplementary-material"><p>Class of Evidence: <ext-link ext-link-type="uri" xlink:href="http://NPub.org/coe">NPub.org/coe</ext-link></p></fn></fn-group><ack><title>Acknowledgment</title><p>The authors thank Dr. Kevan VanLandingham (GSK at time of study), Dr. April Thompson (GSK), and Mieke Jobsis (GSK) for contributions to the study; Professor Angela Vincent and Dr. Leslie Jacobson (Nuffield Department of Clinical Neurosciences, University of Oxford, UK) for performing the antibody analysis; and Sam Halliwell, PhD, and Jennie McLean, PhD, of Fishawack Indicia Ltd, UK, for medical writing support, which was funded by GSK, but did not contribute to the study design or acquisition, analysis, or interpretation of data.</p></ack><sec sec-type="contributions"><title>Author contributions</title><p content-type="contributions">Study conception or design: K.H., R.A.G., C.L.B., D.B.S. Acquisition of data: V.B. Data analysis or interpretation: K.H., R.A.G., C.L.B., M.Z.-H., T.J.R., A.B.</p></sec><sec sec-type="funding"><title>Study funding</title><p content-type="funding">This study was funded by GlaxoSmithKline (study number BEL115123).</p></sec><sec sec-type="disclosure"><title>Disclosure</title><p content-type="disclosure">K. Hewett is an employee of GSK and holds shares in the company. D. Sanders: consultant to GSK, UCB, Accordant Health Services, and Jacobus Pharmaceutical Co. R. Grove is an employee of GSK and holds shares in the company. C. Boderick is an employee of GSK and holds shares in the company. T. Rudo is an employee of GSK and holds shares in the company. A. Bassiri is an employee of GSK and holds shares in the company. M. Zvartau-Hind is an employee of GSK and holds shares in the company. V. Bril: consultant to Bionevia, CSL Behring, UCB, Grifols, Octapharma, Argenx, and Alpha Cancer Technologies, and research funding from CSL Behring, UCB, Grifols, Octapharma, and Argenx. Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000005323">Neurology.org/N</ext-link> for full disclosures.</p></sec><glossary><title>Glossary</title><def-list><def-item><term id="G1">AChR</term><def><p>acetylcholine receptor</p></def></def-item><def-item><term id="G2">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="G3">AESI</term><def><p>adverse events of special interest</p></def></def-item><def-item><term id="G4">BLyS</term><def><p>B-lymphocyte stimulator</p></def></def-item><def-item><term id="G5">Ig</term><def><p>immunoglobulin</p></def></def-item><def-item><term id="G6">ITT</term><def><p>intention-to-treat</p></def></def-item><def-item><term id="G7">LOCF</term><def><p>last observation carried forward</p></def></def-item><def-item><term id="G8">MG</term><def><p>myasthenia gravis</p></def></def-item><def-item><term id="G9">MG-ADL</term><def><p>Myasthenia Gravis Activities of Daily Living</p></def></def-item><def-item><term id="G10">MGC</term><def><p>Myasthenia Gravis Composite</p></def></def-item><def-item><term id="G11">MGFA</term><def><p>Myasthenia Gravis Foundation of America</p></def></def-item><def-item><term id="G12">MMRM</term><def><p>mixed model for repeated measures</p></def></def-item><def-item><term id="G13">MuSK</term><def><p>muscle-specific tyrosine kinase</p></def></def-item><def-item><term id="G14">PLEX</term><def><p>plasma exchange</p></def></def-item><def-item><term id="G15">PP</term><def><p>per protocol</p></def></def-item><def-item><term id="G16">QMG</term><def><p>Quantitative Myasthenia Gravis</p></def></def-item><def-item><term id="G17">SAE</term><def><p>serious adverse events</p></def></def-item><def-item><term id="G18">SLE</term><def><p>systemic lupus erythematosus</p></def></def-item><def-item><term id="G19">SoC</term><def><p>standard of care</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melzer</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ruck</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fuhr</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society</article-title>. <source>J Neurol</source>
<year>2016</year>;<volume>263</volume>:<fpage>1473</fpage>&#x02013;<lpage>1494</lpage>.<pub-id pub-id-type="pmid">26886206</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Wolfe</surname><given-names>GI</given-names></name>, <name name-style="western"><surname>Benatar</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>International consensus guidance for management of myasthenia gravis: executive summary</article-title>. <source>Neurology</source>
<year>2016</year>;<volume>87</volume>:<fpage>419</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">27358333</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Sathasivam</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sharshar</surname><given-names>T</given-names></name></person-group>
<article-title>Immunosuppressive agents for myasthenia gravis</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2007</year>;<volume>4</volume>:<fpage>CD005224</fpage>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Salem</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yassin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Al-Hayk</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yahya</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Al-Shorafat</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dahbour</surname><given-names>SS</given-names></name></person-group>
<article-title>Treatment of MuSK-associated myasthenia gravis</article-title>. <source>Curr Treat Options Neurol</source>
<year>2014</year>;<volume>16</volume>:<fpage>283</fpage>.<pub-id pub-id-type="pmid">24504626</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cordts</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bodart</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hartmann</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis</article-title>. <source>J Neurol</source>
<year>2017</year>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis</article-title>. <source>J Clin Invest</source>
<year>2013</year>;<volume>123</volume>:<fpage>5190</fpage>.<pub-id pub-id-type="pmid">24200689</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Evoli</surname><given-names>A</given-names></name></person-group>
<article-title>Immunosuppressive therapies in myasthenia gravis</article-title>. <source>Autoimmunity</source>
<year>2010</year>;<volume>43</volume>:<fpage>428</fpage>&#x02013;<lpage>435</lpage>.<pub-id pub-id-type="pmid">20166870</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Vincent</surname><given-names>A</given-names></name></person-group>
<article-title>Pathogenesis of myasthenia gravis: update on disease types, models and mechanisms</article-title>
<source>F1000res</source>
<year>2016</year>;<volume>5</volume>:<fpage>F1000</fpage>.</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Main</surname><given-names>SH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator</article-title>. <source>Arthritis Rheum</source>
<year>2003</year>;<volume>48</volume>:<fpage>3253</fpage>&#x02013;<lpage>3265</lpage>.<pub-id pub-id-type="pmid">14613291</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="book"><collab>GSK</collab>. <article-title>Benlysta-pi-mg full prescribing information</article-title>. <publisher-loc>Brentford, UK</publisher-loc>: <publisher-name>GSK</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisak</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Ragheb</surname><given-names>S</given-names></name></person-group>
<article-title>The role of B cell-activating factor in autoimmune myasthenia gravis</article-title>. <source>Ann NY Acad Sci</source>
<year>2012</year>;<volume>1274</volume>:<fpage>60</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">23252898</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Moon</surname><given-names>JS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Serum BAFF expression in patients with myasthenia gravis</article-title>. <source>J Neuroimmunol</source>
<year>2008</year>;<volume>199</volume>:<fpage>151</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">18586330</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scuderi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Alboini</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Bartoccioni</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Evoli</surname><given-names>A</given-names></name></person-group>
<article-title>BAFF serum levels in myasthenia gravis: effects of therapy</article-title>. <source>J Neurol</source>
<year>2011</year>;<volume>258</volume>:<fpage>2284</fpage>&#x02013;<lpage>2285</lpage>.<pub-id pub-id-type="pmid">21559937</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Phan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Siddiqi</surname><given-names>ZA</given-names></name></person-group>
<article-title>Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up</article-title>. <source>Ann Clin Transl Neurol</source>
<year>2016</year>;<volume>3</volume>:<fpage>552</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">27386504</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Manera</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Martinez-Hernandez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Querol</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Long-lasting treatment effect of rituximab in MuSK myasthenia</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>78</volume>:<fpage>189</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">22218276</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iorio</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Damato</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Alboini</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Evoli</surname><given-names>A</given-names></name></person-group>
<article-title>Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis</article-title>. <source>J Neurol</source>
<year>2015</year>;<volume>262</volume>:<fpage>1115</fpage>&#x02013;<lpage>1119</lpage>.<pub-id pub-id-type="pmid">25308632</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Barohn</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Cutter</surname><given-names>GR</given-names></name>, <etal>et al</etal></person-group>
<article-title>A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis</article-title>. <source>Muscle Nerve</source>
<year>2013</year>;<volume>48</volume>:<fpage>76</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">23512355</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furie</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Petri</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zamani</surname><given-names>O</given-names></name>, <etal>et al</etal></person-group>
<article-title>A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>2011</year>;<volume>63</volume>:<fpage>3918</fpage>&#x02013;<lpage>3930</lpage>.<pub-id pub-id-type="pmid">22127708</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navarra</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Guzm&#x000e1;n</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Gallacher</surname><given-names>AE</given-names></name>, <etal>et al</etal></person-group>
<article-title>Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>377</volume>:<fpage>721</fpage>&#x02013;<lpage>731</lpage>.<pub-id pub-id-type="pmid">21296403</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><collab>World Medical Association</collab>. <article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source>JAMA</source>
<year>2013</year>;<volume>310</volume>:<fpage>2191</fpage>&#x02013;<lpage>2194</lpage>.<pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaretzki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Barohn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ernstoff</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Myasthenia gravis recommendations for clinical research standards</article-title>. <source>Neurology</source>
<year>2000</year>;<volume>55</volume>:<fpage>16</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">10891897</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barohn</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>McIntire</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Herbelin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wolfe</surname><given-names>GI</given-names></name>, <name name-style="western"><surname>Nations</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bryan</surname><given-names>WW</given-names></name></person-group>
<article-title>Reliability testing of the Quantitative Myasthenia Gravis score</article-title>. <source>Ann NY Acad Sci</source>
<year>1998</year>;<volume>841</volume>:<fpage>769</fpage>&#x02013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">9668327</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burns</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Conaway</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>DB</given-names></name></person-group>
<article-title>The MG Composite: a valid and reliable outcome measure for myasthenia gravis</article-title>. <source>Neurology</source>
<year>2010</year>;<volume>74</volume>:<fpage>1434</fpage>&#x02013;<lpage>1440</lpage>.<pub-id pub-id-type="pmid">20439845</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolfe</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Herbelin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Nations</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Foster</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bryan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Barohn</surname><given-names>R</given-names></name></person-group>
<article-title>Myasthenia gravis activities of daily living profile</article-title>. <source>Neurology</source>
<year>1999</year>;<volume>52</volume>:<fpage>1487</fpage>&#x02013;<lpage>1489</lpage>.<pub-id pub-id-type="pmid">10227640</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>P</given-names></name></person-group>
<article-title>Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches</article-title>. <source>Pharm Stat</source>
<year>2008</year>;<volume>7</volume>:<fpage>93</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">17351897</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>DA</given-names></name></person-group>
<article-title>Bayesian clinical trials</article-title>. <source>Nat Rev Drug Discov</source>
<year>2006</year>;<volume>5</volume>:<fpage>27</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">16485344</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Katzberg</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nabavi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bril</surname><given-names>V</given-names></name></person-group>
<article-title>The Quantitative Myasthenia Gravis score: comparison with clinical, electrophysiological, and laboratory markers</article-title>. <source>J Clin Neuromuscul Dis</source>
<year>2012</year>;<volume>13</volume>:<fpage>201</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">22622164</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benatar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Burns</surname><given-names>TM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Recommendations for myasthenia gravis clinical trials</article-title>. <source>Muscle Nerve</source>
<year>2012</year>;<volume>45</volume>:<fpage>909</fpage>&#x02013;<lpage>917</lpage>.<pub-id pub-id-type="pmid">22581550</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Struemper</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>W</given-names></name></person-group>
<article-title>Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus</article-title>. <source>J Clin Pharmacol</source>
<year>2013</year>;<volume>53</volume>:<fpage>711</fpage>&#x02013;<lpage>720</lpage>.<pub-id pub-id-type="pmid">23681782</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginzler</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Merrill</surname><given-names>JT</given-names></name>, <etal>et al</etal></person-group>
<article-title>Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source>
<year>2014</year>;<volume>41</volume>:<fpage>300</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="pmid">24187095</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Burns</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Cutter</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Massey</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Juel</surname><given-names>VC</given-names></name>, <name name-style="western"><surname>Hobson-Webb</surname><given-names>L</given-names></name></person-group>
<article-title>Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?</article-title>
<source>Muscle Nerve</source>
<year>2014</year>;<volume>49</volume>:<fpage>483</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">23835683</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Stohl</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Furie</surname><given-names>RA</given-names></name>, <etal>et al</etal></person-group>
<article-title>A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source>
<year>2009</year>;<volume>61</volume>:<fpage>1168</fpage>&#x02013;<lpage>1178</lpage>.<pub-id pub-id-type="pmid">19714604</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sieb</surname><given-names>J</given-names></name></person-group>
<article-title>Myasthenia gravis: an update for the clinician</article-title>. <source>Clin Exp Immunol</source>
<year>2014</year>;<volume>175</volume>:<fpage>408</fpage>&#x02013;<lpage>418</lpage>.<pub-id pub-id-type="pmid">24117026</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tandan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hehir</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Waheed</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Howard</surname><given-names>DB</given-names></name></person-group>
<article-title>Rituximab treatment of myasthenia gravis: a systematic review</article-title>. <source>Muscle Nerve</source>
<year>2017</year>;<volume>56</volume>:<fpage>185</fpage>&#x02013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">28164324</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>J</given-names></name></person-group>
<article-title>REGAIN: a randomized, double-blind, placebo-controlled multi-center phase 3 study of the safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis</article-title>. Presented at the 14th International Congress on Neuromuscular Diseases (ICNMD); July 7, 2016; Toronto.</mixed-citation></ref></ref-list></back></article>